







LPulmonary metastasectomy for colorectal cancer: Making the case
for a randomized controlled trial in the zone of uncertaintyFrancesca Fiorentino, PhD,a and Tom Treasure, MD, MS, FRCS, FRCPbSurvival after pulmonary metastasectomy, from the
earliest to the most recent reports, has been related to
the number of metastases and the time to their appear-
ance. The fewer the metastases and the longer the
interval between primary surgery and metastasectomy,
the better is survival.1 Many clinical reports (by now
there are>100 for colorectal cancer) have implied that
survival is gained by pulmonary metastasectomy and
have encouraged widening the indications. A survey of
members of the European Society of Thoracic Surgeons,
from November 2006 through January 2007, found that
the large majority of responding surgeons (86%) placed
no upper limit on the number of pulmonary metastases
they were prepared to resect and 64% would perform
a metastasectomy within a year of the primary cancer
surgery.2 An alternative explanation for the association
between metastasectomy and longer survival is that
careful selection of patients with favorable prognostic
features, which is central to the management of these
patients, gathers in patients likely to survive longer.
Observational studies with larger numbers of patients
and better statistical analyses have shown that the old
rules still apply and a more liberal implementation of
pulmonary metastasectomy is associated with diminish-
ing returns or worse, and it becomes evident that benefit
in these patients is improbable and therefore they should
be excluded.1,3 In this brief review we examine
observational data and mathematic modeling. We
conclude that a clinical trial, focusing on the zone of
uncertainty, is needed. The Pulmonary Metastasectomy
in Colorectal Cancer (PulMiCC) trial, based on that
reasoning, is recruiting patients in Europe (http://www.
rbht.nhs.uk/research/cteu/projects/respiratory-disease/
pulmicc/).From the Department of Cardiothoracic Surgery,a National Heart and Lung Institute,
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METASTASECTOMY FROM THE ANALYSIS OF
OBSERVATIONAL DATA
The number of metastases has a large effect on survival
after pulmonary metastasectomy, which has been observed
in individual reports and in aggregated data since the Inter-
national Registry of Lung Metastases.4 Solitary metastases
constitute 60% of the 3504 cases in the most inclusive of
the systematic reviews.5 The favorable effect of a longer
interval after primary resection is also a consistent observa-
tion and the average interval in published series is 2 to 3
years.1 To extrapolate from series dominated by patients
with inherently favorable prognostic features, to a wider
group with unfavorable characteristics, will not be associ-
ated with as favorable survival rates.
A combined report from Duke and Memorial Sloan-
Kettering Cancer Center in 2009 appeared to be the first to
recommend explicit limits to metastasectomy for colorectal
cancer.3 The investigators reported that of 44 patients with 3
or more lesions who had a pulmonary metastasectomy less
than 1 year after the primary resection, ‘‘none was cured
by operation.’’3 Their recommendation is quite explicit that
medical management alone should be considered standard
for patients who have both 3 or more pulmonary metastases
and less than a 1-year interval since the primary cancer resec-
tion. In February 2013 the latest systematic review, including
a sophisticated meta-analysis of surgical follow-up studies,
reported that patients with more than a solitary metastasis
were significantly more likely to have a recurrence.1 This
was a consistent finding among studies from 2001 to 2011,
from which they derived the data for analysis providing
‘‘robust information regarding nearly 3000 patients,’’ but
then opined, ‘‘it seems currently unfair to deny surgery for
those patients with two to four lesions.’’1 If the evidence
indicates that the likelihood of benefit is very uncertain
then it seems to us to be fair to communicate that explicitly
to patients so that they fully appreciate that avoiding unavai-
ling surgery is a reasonable course of action. Furthermore,
the responsibility should be borne by the medical profession
to obtain the evidence to better inform patients’ choice.
MATHEMATIC MODELING OF SURVIVAL OF
PATIENTS WITH METASTATIC COLORECTAL
CANCER
Before considering a trial it is important to explore all
available means of discerning the signal, which in this
instance is longer survival attributable to metastasectomy,ery c October 2013
FIGURE 1. A, The data on the Dukes’ stage mix and the disease-free
interval in a cohort of 144 patients who had pulmonary metastasectomy
were used to construct a model to estimate survival among patients in
the Thames Cancer Register matched for Duke stage. The inclusion of
registry patients in the model was conditional on having survived, to be
available for metastasectomy, for an interval equivalent to the disease-
free interval provided in the clinical report of McCormack et al.6 The
reported 5-year survival rate (with 95% confidence intervals) is shown.
B, The same exercise performed with respect to a cohort of 159 patients
in Japan.7 Reprinted with permission.8







Lfrom the noise, which is represented by heterogeneity of
pathology and the effects of multiple treatments. Two large
reports from the 1990s with 144 and 159 patients6,7
provided data on 2 prognostic features that also are
recorded for patients in the Thames Cancer Registry.8
One is the colorectal cancer stage at the time of primary
resection, and the other is the so-called disease-free inter-
val. A modeling exercise has been performed using data
from the registry and from the published cohorts. Registry
patients with a similar mix of cancer stage were identified.
Among these were selected patients who had survived for a
‘‘death-free interval’’6 (and thus were available for further
surgery) similar to the disease-free interval of patients
reported in the cohorts. The survival of patients included
in the models, selected on those 2 criteria, was similar to
that in the reported metastasectomy cohort (Figure 1).
It is notable that patients with metastases at the time of
registration had a survival rate of more than 5% at 5 years.
The process of clinical selection for metastasectomy
preferentially would include these survivors.9 The models
indicate uncertainty concerning benefit attributable to
pulmonary metastasectomy but cannot prove that this
surgery has no effect; a randomized trial is required.
PREDICTIVE OR PROGNOSTIC?
It is important to emphasize the distinction between the
words prognostic and predictive.10 A prognostic factor is
a variable that can be known before starting the treatment.
Variation in survival is influenced by these factors
regardless of which treatment the patient receives. The
number of metastases and the interval before they appear
are prognostic factors, as is carcinoembryonic antigen
(CEA). A predictive factor relates to treatment responsive-
ness. Thus, failure to achieve R0 resection is predictive of a
poor outcome but cannot be known until after surgery and
therefore cannot be used reliably in selection. Mediastinal
nodal involvement is both an adverse prognostic feature
when it is known before surgery and predictive of poorer
survival if discovered at surgery. In reports of pulmonary
metastasectomy, predictive and prognostic factors often
are listed together, as they were by Gonzalez et al,1 who
listed 4 factors that increased the probability of death by a
factor of 2 in the meta-analysis: more than 1 metastasis,
synchronous lung metastasis, involvement of thoracic
lymph nodes, and increased prethoracotomy CEA.
CEA AND SURGERY FOR ADVANCED
COLORECTAL CANCER
The CEA assay has an instructive history. Its use in
surveillance after primary resection of colorectal cancer
was evaluated in the Cancer Research Campaign CEA
Second-Look Trial. This tested the concept that early
recurrence in pelvic or mesenteric lymph nodes, the
retroperitoneum, the liver, or at the colonic anastomosisThe Journal of Thoracic and Camight be resected successfully, providing a second chance
of achieving cure. Patients with increased CEA were
allocated randomly to have, or not to have, a second-look
laparotomy.11 Patients undergoing a second-look laparo-
tomy did not have better survival. The patients undergoing
a second-look laparotomy had more investigations,
hospitalizations, and surgery, but did not live longer. The trial
was stopped by the data monitoring committee after 1447
patients had been registered and 216 patients had been
randomized. Harm had been caused, without benefit, and it
was improbable that any benefit would ever be shown.
Included in the second-look laparotomy protocol was
mobilization of the liver in line with the growing practice
of liver resection for colorectal metastases.12 There was,
at the time, an opportunity to perform a trial of liver
resection effectiveness. A power calculation published by
the Mayo Clinic indicated that 36 randomized patientsrdiovascular Surgery c Volume 146, Number 4 749
FIGURE 2. Among 300 patients with pulmonary metastases, there are
15 patient (5%) destined to live for 5 years after their primary colorectal
cancer surgery based on cancer registry data that are on the conservative
side. The patients have been sorted according to the number of metastases
and the interval since the primary resection. The 15 patients destined to
survive are likely to have fewer metastases and longer intervals and might
be clustered as shown toward the top right of the matrix. If we now apply
the usual selection criteria to select 1 in 12 patients, this might include 10 of
the predestined survivors among these 25 patients. The 40% (10 of 25)
inclusion of green figures is the result of sorting and selection, but
incorrectly could be attributed to the fact that they underwent surgery.9
Reprinted with permission.9







Lwould have been sufficient to prove effectiveness of the
metastasectomy if the 25% 5-year survival rate among
those undergoing liver resection was largely attributable
to surgery.13 The trial was not performed and instead
hepatic resection went into standard clinical care without
secure evidence.
With respect to CEA we are now faced with a dilemma.
When used in surveillance, after resection of primary colon
cancer, an increase in CEA prompts further imaging. Lung
nodules are the most visible recurrence, and are easily seen
radiologically against the blackness of an air-filled lung.
But a CEA increase has long been known to be associated
with poorer survival after pulmonary metastasectomy.
Here is the paradox: the same blood test that prompted
referral for consideration of pulmonary metastasectomy
may then be grounds to turn the patient away from thoracic
surgery. CEA did not appear in the Duke–Memorial
Sloan-Kettering Cancer Center study3 as a risk factor for
death. This was probably because the range of CEA levels
among surgical cohorts was restricted because clinicians
applied the evidence already widely available.5
THE CURRENT PRACTICE OF PULMONARY
METASTASECTOMY FOR COLORECTAL
CANCER
For the Gonzalez et al1 meta-analysis, although the date
limit on publications for inclusion was set at 2001, patients
included were from as far back as the 1980s. How do these
data for patient inclusion reflect current practice? There are
newly published data from the Grupo Espa~nol de Cirugıa
Metastasis Pulmonares de Carcinoma Colo-Rectal (the
Spanish Group for Surgery of Pulmonary Metastases from
Colorectal Cancer). The study reported a prospective
registry of 543 patients from 2008 to 2010 who represented
an estimated 60% of all Spanish patients undergoing
metastasectomy.14 In 55% of patients there was a solitary
metastasis. The median interval between the primary
cancer resection and metastasectomy was 28 months. This
is consistent with the International Registry of Lung
Metastases from the 1990s,4 the collected series in the
meta-analysis including patient from the 1980s,1 and
clinical reports back to the 1970s.5 What is different is
that in more recent practice metastatic disease was present
in the liver in 29% of patients at one or more time points
before pulmonary metastasectomy.14
Estimates of the degree of case selection are impossible
to derive from the clinical reports of eminent institutions
because we have no way of knowing the denominator
from which they were drawn and many patients are
secondary or tertiary referrals. The Spanish Group’s study
estimated that these 543 patients were at most 5% of the
patients with lung metastases from colorectal cancer or
2.5% of all colorectal cancer patients, and they found that
these rates are broadly comparable with Japanese and750 The Journal of Thoracic and Cardiovascular SurgItalian data on case selection.14 At this level of selection
of patients based on prognostic factors (number, interval,
and CEA) a 40% five year survival rate could be attributed
entirely to selection, with no need for any effect of
metastasectomy to explain the outcome (Figure 2).SYMPTOMS AND QUALITY OF LIFE
None of the reviews provide any information on symp-
tomatic benefit. This is not surprising: pulmonary metasta-
sectomy is performed on patients with good performance
status. Symptoms are not a feature of pulmonary metastases
being considered for resection and therefore would not be
retrieved on chart review. In fact, the terminal phase of
the natural history of colorectal cancer is little influenced
by any symptomatic effects of pulmonary metastases and
they very infrequently contribute to death. In PulMiCC,
patient-reported outcomes, measures of quality of life,
and specifically respiratory symptoms, will be recorded.
Respiratory benefit is not anticipated whereas detrimental
effects must be ascertained in the evaluation of overall
effectiveness of pulmonary metastasectomy.THE PulMiCC TRIAL
A few patients with a solitary metastasis might have
the only residue of their cancer removed and indefiniteery c October 2013
FIGURE 3. Trial flow chart. The decision-making area of the chart runs vertically in the center of the flowchart. Red areas of the chart indicate patients
selected by the local multidisciplinary team to not have surgery, and green indicates those selected to have surgery. Amber indicates uncertainty. The first
uncertainty (to the right) is whether a solitary nodule is a metastasis. The second (at the bottom) is whether there is clinical agreement on whether the
patient should or should not have a metastasectomy. PulMiCC, Pulmonary Metastasectomy in Colorectal Cancer. MDT, Multidisciplinary team;
MDM, multidisciplinary meeting.







Lsurvival attributed to the metastasectomy. How often that
occurs cannot be derived from the available evidence so
we concluded that a survival gain attributed to metastasec-
tomy was unproven. The proposal therefore arose to put
pulmonary metastasectomy to the fair test of a randomized
controlled trial. Randomized controlled trials in surgery
appear to some to be a forlorn hope: akin to putting a
square peg in a round hole.15 However, there is a very
substantial hole in our knowledge concerning the effective-
ness of pulmonary metastasectomy; the trick surely is to
use imagination and expertise in trial design to fashion a
research peg to fit the hole in the evidence. The essence
of the PulMiCC trial is that it is based on real-world
practice: most patients with pulmonary metastases from
colorectal cancer do not have a metastasectomy for a
range of reasons related to the characteristics of the
patient and the behavior of the cancer. Only a minority
are selected. It follows that if there is yes for some and no
for others, there must be debatable cases for which it
seems unfair to deny1 surgery or for whom the benefit of
the doubt is invoked. These are the patients in whom
there is manifest uncertainty and to whom randomized
allocation can be offered. The inclusion of patients thus
is determined by local belief, practice, and convictions,
and is not dictated by the clinical trial protocol. The trial
design ensures balance within any given trial center.
Variation in perception of where uncertainty lies broadens
inclusion and will make the result more generalizable.
Outcomes of interest in the study were survival and quality
of life.The Journal of Thoracic and CaThe trial therefore has 2 stages (Figure 3). In the first
stage, without any commitment to randomization, patients
who have had curative resection of their primary cancer
and are found to have pulmonary metastatic disease, are
fully assessed and fully informed, just as in current best
practice. Many patients are found to have features that
would make benefit improbable. At the other end of the
distribution are those who have such favorable characteris-
tics that the local team wants to recommend surgery and the
patient wants to accept it. It is those in the middle, for whom
uncertainty becomes manifest, who are offered random
allocation. The PulMiCC trial is recruiting in Europe.
Full details of the trial can be obtained from the trial center
at Royal Brompton Hospital (http://www.rbht.nhs.uk/
research/cteu/projects/respiratory-disease/pulmicc/). More
than 160 patients are in the study at the time of writing
with approximately a third of them going forward for
random allocation for whether or not to have pulmonary
metastasectomy.
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